Childhood nephrotic syndrome—current and future therapies
Transcript of Childhood nephrotic syndrome—current and future therapies
![Page 1: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/1.jpg)
G R E E N B A U M , L . A . E T A L .
N A T . R E V . N E P H R O L . 8 , 4 4 5–4 5 8 ( 2 0 1 2 ) ; P U B L I S H E D O N L I N E 1 2 J U N E 2 0 1 2 ;
A T U L D E S A I 1 0 / 8 / 1 2
Childhood nephrotic syndrome—current and future therapies
![Page 2: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/2.jpg)
BACKGROUND
Not a single disease
• Genetic mutations• Circulating factors• T cell or B cell
abnormality
Podocyte injury
Nephrotic syndrome
• MCD• FSGS• MsGN• MPGN• MN
![Page 3: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/3.jpg)
Mortality rate
Prior to antibiotics & steroids 67 %
Introduction of sulfonamides 42%
Introduction of Penicillins 35%
Introduction of ACTH 5%
![Page 4: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/4.jpg)
Definitions
Nephrotic syndrome: • Edema• Proteinuria: >40mg/sq m/hr
or > 50mg/kg/day or PCR : >2 g/g 3+ protein on dipstick
• Hypoalbuminemia : <2.5 g/dl• Hyperlipdemia
Prednisolone Rx2mg/kg/day x 6wk1.5mg/kg alt day x 6wk
• uPCR <200mg/g• <1+ protein on dipstick
for 3 consecutive daysCOMPLETE REMISSION
• Proteinuria reduction by > 50 % from presenting value and
• uPCR 200- 2000 mg/g
PARTIAL REMISSION
Resistance if no CR by 8 wk of Rx
![Page 5: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/5.jpg)
Relapse : uPCR > 2g/g or > 3 + proteinuria on dipstick test for 3 consecutive days.
Infrequent : 1 relapse within 6 months of initial response, or one to three relapses in any 12-month period
Frequent : Two or more relapses within 6 months of initial response, or four or more relapses in any 12-month period
SDNS: Two consecutive relapses during corticosteroid therapy, or within 14 days of ceasing therapy
![Page 6: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/6.jpg)
Response of NS to Rx
Idiopathic NS
Steroid sensitive
90%
Steroid resistant
10%
40% 60%
Infrequent relapse
FRNSSDNS
• ALKYLATING AGENTS
• CNI• MMF• RITUXIMAB
![Page 7: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/7.jpg)
CURRENTLY AVAILABLE Rx FOR SDNS/FRNS/SRNS
Corticosteroid : low dose for long period in FRNS/SDNS
IV glucocorticoids :High dose IV steroid can sometimes induce remission in SRNS18 month protocol of IV CS +/- CYC in SRNS is effective
Methylprednisolone treatment of patients with SRNSF. Bryson Waldo, Mark R. Benfield and Edward C. Kohaut
PEDIATRIC NEPHROLOGYVolume 6, Number 6 (1992), 503-505,
13 pts: 8 blacks, 5 white10 had FSGS on Bx, 3 nil lesionInitial response: 5 had complete response; 2 PROf responded pts, 5 relapsed while on a;t week MP rx3 of them received 2nd course of MP+ chlorambucol : 2 respondedObserved for mean of 47 months (6-64 months)3 pts with nil disease : proteinuria free6 have ESRD2 renal; insufficiencyBlacks : no response
MP 20 mg/kg : on Mon, Wed, Fri for 2 weeksWeekly for 8weeks
Every other week for 8 weeksMonthly for 10 months
![Page 8: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/8.jpg)
CYTOTOXIC DRUGS
Cyclophosphamide and chlorambucil
Cyclophosphamide: CD not to exceed 168 mg/kg
![Page 9: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/9.jpg)
CNIS
Cyclosporine & Tacrolimus
prevents T-cell activation through inhibition of calcineurin-induced IL2 gene expression
Also stabilize podocyte actin cytoskeleton
in a nonrandomized trial, 65 children with SRNS (45 with MCD; 20 with FSGS) were treated with a combination of ciclosporin and prednisone, with 27 children (41%) achieving complete remission.
In a randomized study published in 2008, ciclosporinwas superior to intravenous cyclophosphamide in children with SRNS.
![Page 10: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/10.jpg)
MMF
IMPDH inhibitor
No salvage pathway in lymphocytes
1200mg/mt sq in 2 divided dose.
Various uncontrolled study : MMF beneficial in FRNS/SRNS
![Page 11: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/11.jpg)
Plasmapheresis
Only few case report of its use in native kidney nephrotic syndrome.
![Page 12: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/12.jpg)
NEW APPROACHES
Rituximab
Galactose
Adalimumab
Thiazolidinediones
![Page 13: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/13.jpg)
RITUXIMAB
Chimeric monoclonal antibody that
Depletes CD20+ B cells.
Use in Nephrology :
• Microscopic polyangiitis and granulomatosis with polyangiitis (Wegener) (FDA approval in 2011)
• Posttransplant lymphoproliferative disorder• Lupus nephritis• Membranous nephropathy• Recurrence of nephrotic syndrome in patients
with FSGS following transplantation• Nephrotic syndrome.
![Page 14: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/14.jpg)
RITUXIMAB in SDNS/FRNS
54 children (mean age 11 +/- 4 years) with INS dependent on prednisone and calcineurin inhibitors for >12 months were randomized. Rituximab and lower doses of prednisone and calcineurin inhibitors are noninferior to standard therapy in maintaining short-term remission in children with INS dependent on both drugs and allow their temporary withdrawal.
![Page 15: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/15.jpg)
In a retrospective comparison of 23 children with SDNS, rituximab and tacrolimus were similarly effective in reducing relapse rates and glucocorticoid exposure
In another retrospective study of 30 children with SDNS treated with repeated doses of rituximab to maintain depressed CD19 levels for at least 15 months, long-term remission (~17 months) following complete CD19 recovery was noted in 19 (63%) of patients.
![Page 16: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/16.jpg)
a retrospective review of long-term outcomes for 37 children with SDNS found that 375 mg/m2 given weekly for 1–4 courses resulted in a sustained remission in 26 children (70%) for 12 months and, among 29 children followed for more than 2 years, 12 (41%) remained in remission
![Page 17: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/17.jpg)
RITUXIMAB IN SRNS
• 33 children with SRNS who received 2–4 doses of rituximab. • At 6 months after the last dose of rituximab: 9 (27%) children had
entered complete remission, 7 (21%) had experienced a partial remission, and 17 (51%) had had no response.
• The median time to response was 32 days (8–60 days),
![Page 18: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/18.jpg)
RITUXIMAB: DOSING
Appropriate dosing not known
375 mg/ sq mt every wk : 1-4 dose – commonly used.
Most have complete B cell depletion after single dose
The total Rituximab dose doesn’t correlate with clinical outcome
![Page 19: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/19.jpg)
![Page 20: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/20.jpg)
Rituximab : repeat dose interval
![Page 21: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/21.jpg)
Rituximab : relapse
Relapse time : variable. Usually 5-9 month
Often associated with repopulation of CD 20 + B cells
![Page 22: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/22.jpg)
![Page 23: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/23.jpg)
Rituximab : Mode of action in NS
Rituximab binds directly to an acid sphingomyelinase-like phosphodiesterase 3b (SMPDL3B) on the surface of podocytes.
The binding of rituximab to this ‘off-target’ podocyte protein prevented the downregulation of acid sphingomyelinase activity in cultured podocytesinduced by sera from adults with recurrent FSGS, as well as restored actin stress fiber formation and podocyte viability.
![Page 24: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/24.jpg)
GALACTOSE
Novel Rx option in NS
Binds permeability factor in pts with FSGS
Alters the glomerular permeability.
![Page 25: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/25.jpg)
![Page 26: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/26.jpg)
Adalimumab
Monoclonal anti TNF antibody
Binds to TNF, prevents its binding to its receptor.
![Page 27: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/27.jpg)
Thiazolidinediones
Thiazolidinediones reduced proteinuria, microalbuminuria, podocyte injury, vascular injury, inflammation and fibrosis in both diabetic nephropathy and nondiabetic glomerulosclerosis in mouse and rat models, as well as in humans.
![Page 28: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/28.jpg)
The thiazolidinedione pioglitazone protected against progression of puromycin aminonucleoside (PAN)-induced glomerulosclerosis in vivo and against injury of cultured podocytes in vitro.
Thiazolidinediones markedly decreased albuminuria and proteinuria in patients with diabetes mellitus
![Page 29: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/29.jpg)
![Page 30: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/30.jpg)
Future treatments
p38 MAPK, MK2 and PKCα signaling
Notch signaling
Targeting IL-13
Suppressing the unfolded protein response
Maintaining redox homeostasis
![Page 31: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/31.jpg)
MAPK: signalling
The major families of MAPK typically translate extracellular stimuli to intracellular responses.
The p38 MAPK pathway has crucial roles in inflammation, differentiation, senescence, tumorigenesis, and apoptosis, as well as in a variety of renal diseases
![Page 32: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/32.jpg)
The various forms of protein kinase C (PKC) also have a role in both glomerular and tubular function
PKC λ deletion : nephrotic syndrome
PKC α deletion : prevents NS
![Page 33: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/33.jpg)
NOTCH SIGNALLING
Notch signaling regulates multiple cellular processes including development, differentiation, proliferation and apoptosis.
In mammals, there are four Notch (Notch 1–4) and five ligand (Jagged1, Jagged2, DLL1, DLL3, DLL4) genes.
all containing transmembrane domains such that ligand-receptor signaling occurs between adjacent cells
Play crucial role in nephrogenesis.
![Page 34: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/34.jpg)
Notch signaling involves receptors, ligands, modifiers, and transcription factors.
Following Jagged or Delta-like protein ligand binding, the intracellular domain of the Notch receptor is cleaved off by a γ-secretase and subsequently translocated to the nucleus where it binds to the transcriptional repressor RBP-J
![Page 35: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/35.jpg)
Niranjan and co-workers demonstrated that transgenic mice conditionally overexpressing Notch-ICD in mature podocytes developed proteinuria and glomerulosclerosis, in association with p53 activation and podocyte apoptosis.
Conversely, genetic deletion of downstream Rbpj in the podocytes of mice with diabetes protected against glomerular proteinuria, as did pharmacologic inhibition of the upstream γ-secretase in rats with PAN-induced proteinuria.
![Page 36: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/36.jpg)
IL 13
Lebrikizumab = IL 13 antibody
![Page 37: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/37.jpg)
Supressing unfolded protein response
Stress induced disturbance of protein folding in ER : unfolded protein response.
UPR : recognised as the underlying pathologic mechanism in various diseases.
UPR is a complex signaling program of stress adaption by maintaining protein folding homeostasis.
If folding homeostasis cannot be maintained because of severe stress, programs are activated that initiate autophagy and/or apoptosis.
![Page 38: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/38.jpg)
This cellular stress response has already been recognized as having a pathogenic role in some forms of nephrotic syndrome.
In kidney biopsy samples from adults with nephrotic syndrome associated with FSGS, crescentic glomerulonephritis, membranous glomerulonephritis, and membranoproliferative glomerulonephritis, indicators of the UPR, such as heat shock 70 kDa protein 5 and DNA-damage-inducible transcript 3 are found to be upregulated when compared with patients with MCD, whereas the apoptosis regulator Bcl-2 was downregulated.
![Page 39: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/39.jpg)
The UPR was regulated by the mammalian target of rapamycin (mTOR) complex 1
mTOR inhibitors : reduce proteinuria
![Page 40: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/40.jpg)
The UPR has also been suggested to have a role in some inherited forms of nephrotic syndrome, caused by mutations in nephrin, podocin and α-actinin-4.
![Page 41: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/41.jpg)
Future therapeutic approaches could target stabilization of folding homeostasis in podocytes.
Approaches might include enhancement of protein chaperoning or enhancement of degradation capacities, by increasing the expression of relevant chaperones or proteasome system activity, respectively.
![Page 42: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/42.jpg)
Alternative approaches might include the use of low-molecular mass compounds that reduce misfoldingand protein aggregation, such as sodium 4-phenylbutyrate or (–)-epigallocatechin-3-gallate, which is a secondary plant metabolite.
![Page 43: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/43.jpg)
Maintaining redox homeostasis
Oxidative stress occurs in both children and adults with various kidney diseases.
Reactive oxygen species (ROS) have been suggested to have a role in the pathogenesis of nephrotic syndrome through actions such as impairing the integrity of the glomerular basement membrane or reducing podocyte proteoglycan de novo synthesis
![Page 44: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/44.jpg)
Oxidative injury of podocytes in nephrotic syndrome might also be caused indirectly through increased exposure to oxidized serum albumin
Developing improved, or more targeted, strategies to reduce podocyte oxidative stress and/or regulate redox homeostasis would be an auspicious approach to attenuate podocyte injury in nephrotic syndrome
![Page 45: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/45.jpg)
the radical scavenger edaravone or dietary supplementation with the antioxidants probucol and vitamin E : of modest benefit
![Page 46: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/46.jpg)
TARGETING GENETIC FORM OF NS
Cyclosporine in NS caused by mutation in TRPC6
![Page 47: Childhood nephrotic syndrome—current and future therapies](https://reader035.fdocuments.us/reader035/viewer/2022081502/55a611611a28ab2f5c8b47e8/html5/thumbnails/47.jpg)